A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Trial Profile

A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs SGN CD19B (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 25 Feb 2016 Status changed from planning to recruiting, as reported, as reported by Seattle Genetics media release .
    • 04 Nov 2015 New trial record
    • 29 Oct 2015 According to a Seattle Genetics media release, the company has submitted an investigational new drug (IND) application to the US FDA for SGN-CD19B. This trial is expected to start in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top